Longeveron Raises A Total Of $11.4M In Gross Proceeds From Warrant Exercise Offering And Public Offering
Longeveron Raises A Total Of $11.4M In Gross Proceeds From Warrant Exercise Offering And Public Offering
Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer's disease and Aging-related Frailty, today announced the closing of its previously announced exercise of certain existing warrants to purchase an aggregate of 2,399,744 shares of its Class A common stock having an exercise price of $2.35 per share, originally issued in October 2023 and April 2024. The issuance or resale of the shares of Class A common stock issuable upon exercise of the existing warrants, as applicable, are registered pursuant to effective registration statements on Form S-1 (File Nos. 333-275578 and 333-278073). The Company anticipates that this additional funding will enable it to make significant progress in its HLHS program, including advancing enrollment in the on-going clinical trial towards completion as well as advancing understanding of the potential to use this trial as a pivotal trial for accelerated or final approval of Lomecel-BTM for HLHS.
Longeveron Inc.（納斯達克股票代碼：LGVN）（“Longeveron” 或 “公司”）是一家臨床階段的生物技術公司，爲左心發育不全綜合症（HLHS）、阿爾茨海默氏病和衰老相關虛弱症等危及生命和慢性衰老的疾病開發細胞療法。該公司今天宣佈結束其先前宣佈的某些現有認股權證的行使，總共購買其2399,744股股票行使價爲每股2.35美元的A類普通股，最初於2023年10月和2024年4月發行。行使現有認股權證時可發行的A類普通股的發行或轉售根據S-1表格（文件編號333-275578和333-278073）上的有效註冊聲明進行登記。該公司預計，這筆額外資金將使其能夠在HLHS計劃中取得重大進展，包括將正在進行的臨床試驗的註冊工作推向完成，以及加深對將該試驗用作加速或最終批准Lomecel-BTM用於HLHS的關鍵試驗的可能性的理解。
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
H.C. Wainwright & Co. 擔任本次發行的獨家配售代理。
In consideration for the immediate exercise of the existing warrants for cash and the payment of $0.125 per new warrant, the Company issued new unregistered warrants to purchase up to an aggregate of 4,799,488 shares of Class A common stock. The new warrants are immediately exercisable at an exercise price of $2.35 per share. The new warrants to purchase 2,399,744 shares of Class A common stock have a term of five years from the issuance date, and the new warrants to purchase 2,399,744 shares of Class A common stock have a term of twenty-four months from the issuance.
作爲立即行使現有現金認股權證和支付每份新認股權證0.125美元的考慮，該公司發行了新的未註冊認股權證，總共購買4,799,488股A類普通股。新的認股權證可立即行使，行使價爲每股2.35美元。購買2399,744股A類普通股的新認股權證的期限爲自發行之日起五年，購買2399,744股A類普通股的新認股權證自發行之日起有效期爲二十四個月。
The gross proceeds to the Company from the warrant exercise offering were approximately $6.2 million, prior to deducting placement agent fees and offering expenses payable by the Company. The total gross proceeds to the Company from the two offerings, this warrant exercise offering and the previously announced public offering, with gross proceeds of approximately $5.2 million, which closed on April 10, 2024, in each case, prior to deducting placement agent fees and offering expenses payable by the Company, were approximately $11.4 million. The Company intends to use the net proceeds from the offerings for its ongoing clinical and regulatory development of Lomecel-B for the treatment of several disease states and indications, including HLHS and Alzheimer's disease, obtaining regulatory approvals, capital expenditures, working capital and other general corporate purposes.
在扣除配售代理費和公司應付的發行費用之前，公司從認股權證行使發行中獲得的總收益約爲620萬美元。在扣除配售代理費和公司應付的發行費用之前，公司從兩次發行、本次認股權證行使發行和先前宣佈的公開募股中獲得的總收益約爲520萬美元，總收益約爲520萬美元，均爲1,140萬美元。該公司打算將此次發行的淨收益用於正在進行的Lomecel-B臨床和監管開發，用於治療包括HLHS和阿爾茨海默氏病在內的多種疾病狀態和適應症，獲得監管部門的批准、資本支出、營運資金和其他一般公司用途。
譯文內容由第三人軟體翻譯。